Regeneron Pharmaceuticals, Inc. (REGN) to Issue Quarterly Dividend of $0.94 on August 31st

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) declared a quarterly dividend on Thursday, July 30th. Shareholders of record on Tuesday, August 18th will be paid a dividend of 0.94 per share by the biopharmaceutical company on Monday, August 31st. This represents a c) dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Tuesday, August 18th.

Regeneron Pharmaceuticals has a payout ratio of 9.6% meaning its dividend is sufficiently covered by earnings. Analysts expect Regeneron Pharmaceuticals to earn $50.53 per share next year, which means the company should continue to be able to cover its $3.76 annual dividend with an expected future payout ratio of 7.4%.

Regeneron Pharmaceuticals Stock Down 0.3%

NASDAQ:REGN opened at $803.48 on Friday. The firm has a market capitalization of $82.73 billion, a PE ratio of 19.86, a price-to-earnings-growth ratio of 1.37 and a beta of 0.22. The stock has a 50 day moving average of $675.79 and a 200-day moving average of $714.34. Regeneron Pharmaceuticals has a 52 week low of $541.00 and a 52 week high of $821.11. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. During the same quarter last year, the business posted $12.81 EPS. The business’s revenue was up 16.7% on a year-over-year basis. Analysts predict that Regeneron Pharmaceuticals will post 44.25 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on REGN. Sanford C. Bernstein upgraded Regeneron Pharmaceuticals to a “hold” rating in a research note on Wednesday, July 29th. Canaccord Genuity Group lowered their price target on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a research report on Tuesday, May 19th. JPMorgan Chase & Co. dropped their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a report on Monday, May 18th. Wells Fargo & Company lifted their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a research report on Friday, July 31st. Finally, Piper Sandler reduced their target price on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating for the company in a research note on Thursday, July 9th. Sixteen analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $793.74.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.